Effects of silver nanoparticles–polysaccharide on bleomycin-induced pulmonary fibrosis in rats

Author:

Hassan Amal I1ORCID,Samir Amer2,Youssef Hanan F3,Mohamed Sahar S4,Asker Mohsen S4,Mahmoud Manal G4

Affiliation:

1. Department of Radioisotopes, Nuclear Research Centre, Atomic Energy Authority, Egypt

2. Department of Pathology, National Cancer Institute, Cairo University, Egypt

3. Department of Ceramics, Refractories and Building Materials, National Research Centre, Dokki, Cairo, Egypt

4. Department of Microbial Biotechnology, National Research Centre, Dokki, Cairo, Egypt

Abstract

Abstract Objectives The first goal of this study was to synthesize the silver nanoparticles Alcaligenes xylosoxidans exopolysaccharide (Ag-AXEPS). The second objective was to analyse the role of Ag-AXEPS nanoparticles (NPS) in treating bleomycin (BLM)-induced lung fibrosis. Methods Intratracheal bleomycin (2.5 U/kg) was administered to prompt pulmonary fibrosis in rats, and pulmonary fibrosis was treated with Ag-AXEPS nanoparticles (100 ppm/twice a week for four weeks). Key findings Ag-AXEPS nanoparticles significantly decreased the diversity of pulmonary inflammatory agents in rats with BLM-induced fibrosis. Reduced levels of respiratory tumor necrosis factor-alpha, monocyte chemotactic protein-1, matrix metalloproteinases (MMP-2 and MMP-9) were observed on treatment with synthesized Ag-AXEPS. Similarly, the treatment decreased IL-12, mRNA levels of BAX and plasma fibrosis markers like N-terminal procollagen III propeptide and transforming growth factor-β1. On the other hand, the treatment increased mRNA BCL2 and total antioxidant capacity. It also lowered the level of fibrosis, as was shown by a quantified pathologic study of hematoxylin–eosin-stained lung parts. The treatment, however, ensured that lung collagen was restored, as assessed by Masson’s trichrome stain, and that overall survival was increased and enhanced. Conclusions Our work showed that nanoparticles could be obtained at 37°C and may be a possible pulmonary fibrosis therapeutic agent.

Publisher

Oxford University Press (OUP)

Subject

Pharmaceutical Science,Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3